ESLA Estrella Immunopharma, Inc.
$0.66▼ -1.99%
Healthcare
Other
After hours
$0.65▼ -1.68%
Sep 11, 6:14 PM ET
Volume 25.6K
Avg Volume (10D) 37.2K
Key Metrics & Fundamentals
Market Cap
$28.69M
P/E Ratio
–
Div Yield
–%
52W Range
0.59 - 3.15
% vs 50 MA
-13.15%
% vs 200 MA
-44.01%
RSI-14
38.4
MACD Histogram
+0.0000
Beta (1Y vs SPY)
0.78
Free Cash Flow
-$1.78M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$1.86M
COGS
–
Operating Exp
$2.08M
Operating Income
-$2.08M
EBIT
-$2.08M
Pretax Income
-$2.31M
Net Income
-$2.31M
EPS (Diluted)
-0.05
Price & Volume History
Loading chart…
Recent News
ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial
Zacks Small Cap Research · Aug 26, 2026 12:42 PM
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Business Wire · Aug 11, 2026 12:00 PM
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Business Wire · Aug 3, 2026 12:00 PM
Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Business Wire · Jul 29, 2026 12:00 PM
Estrella Immunopharma's Trial of EB103 to Treat Lymphoma Doses First Patient
MT Newswires · Jul 24, 2026 12:50 PM
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma
Business Wire · Jul 24, 2026 12:00 PM
ESLA: Can Next-Generation CAR-T Therapy Improve Disease Control in Extranodal Lymphoma?
Zacks Small Cap Research · Jul 14, 2026 10:22 AM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ESLA's money flow as a full page
Social Sentiment
No Reddit posts found for ESLA.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.